A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Emanuela RisiAndrea GrilliIlenia MigliaccioChiara BiagioniAmelia McCartneyCristina GuarducciMartina BonechiMatteo BenelliStefania VitaleLaura BiganzoliSilvio BicciatoAngelo Di LeoLuca MalorniPublished in: Breast cancer research and treatment (2018)
Low expression of RBsig identifies a subset of ER+/HER2+ patients with low pCR rates following neoadjuvant chemotherapy ± anti-HER2 therapy. These patients may potentially be spared chemotherapy in favor of anti-HER2, endocrine therapy, and CDK 4/6 inhibitor combinations.
Keyphrases
- neoadjuvant chemotherapy
- gene expression
- end stage renal disease
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- positive breast cancer
- sentinel lymph node
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- dna methylation
- spinal cord injury
- estrogen receptor
- early stage
- spinal cord
- breast cancer cells
- binding protein